Similarly, combination of sorafenib with azacitidine (for FLT3-ITD-mutated AML) or LDAC (for high-risk MDS or AML) did not translate into meaningful survival benefit in untreated elderly patients [57, 58]. The gene discussed is FLT3; the disease is acute myeloid leukemia.